Associated tags: Safety, Drug development, Artificial intelligence, AI, Medical device, Pharmaceutical industry, Patient, Research, Multiple sclerosis, FDA
Locations: ITALY, MILAN, EU, UNITED STATES, EUROPE, AUSTRIA, BELGIUM, FRANCE, GERMANY, NETHERLANDS, SPAIN, SWITZERLAND, UNITED KINGDOM, CM, ALMA, UNITED STATES OF AMERICA, SWEDEN
Algorithm,
DEM,
Alcopop,
Partnership,
Discrete element method,
Processor (computing),
RCPE,
Graphics processing unit,
Publication,
XPS,
FDA,
3D printing The FDA has recently purchased an XPS (eXtended Particle Simulations) license as an in-house simulation tool, reflecting a trend in the agency's engagement with advanced computational technologies.
Key Points:
- The FDA has recently purchased an XPS (eXtended Particle Simulations) license as an in-house simulation tool, reflecting a trend in the agency's engagement with advanced computational technologies.
- XPS is a state-of-the-art Discrete Element Method (DEM) simulation software, developed by RCPE and distributed globally by InSilicoTrials through an exclusive partnership agreement.
- XPS relies on advanced contact models to accurately describe the flow behavior of granular materials.
- The collaboration u-sed XPS to predict Residence Time Distributions (RTDs), for the development of a flowsheet modeling framework based on reduced-order models.
Algorithm,
DEM,
Alcopop,
Partnership,
Discrete element method,
Processor (computing),
RCPE,
Graphics processing unit,
Publication,
XPS,
FDA,
3D printing The FDA has recently purchased an XPS (eXtended Particle Simulations) license as an in-house simulation tool, reflecting a trend in the agency's engagement with advanced computational technologies.
Key Points:
- The FDA has recently purchased an XPS (eXtended Particle Simulations) license as an in-house simulation tool, reflecting a trend in the agency's engagement with advanced computational technologies.
- XPS is a state-of-the-art Discrete Element Method (DEM) simulation software, developed by RCPE and distributed globally by InSilicoTrials through an exclusive partnership agreement.
- XPS relies on advanced contact models to accurately describe the flow behavior of granular materials.
- The collaboration u-sed XPS to predict Residence Time Distributions (RTDs), for the development of a flowsheet modeling framework based on reduced-order models.
Regeneration,
AI,
MD,
Stem cell,
Ageing,
Drug development,
National University Health System,
Telomere,
CHL,
HUVEC,
Conference,
Longevity,
B cell,
NUHS,
MSC,
Poster,
TELO,
Research,
Pharmaceutical industry The data presented was garnered from pre-clinical studies that Telomir previously disclosed it was undertaking.
Key Points:
- The data presented was garnered from pre-clinical studies that Telomir previously disclosed it was undertaking.
- The data presented further demonstrated how Telomir-1 increases telomere length and its potential to successfully affect age-related inflammatory conditions.
- The collaboration is expected to help accelerate the development of Telomir-1, improve its safety profile, and significantly reduce the research and development costs of Telomir’s drug development program.
- To be added to the Telomir Pharmaceuticals email distribution list, please email [email protected] with TELO in the subject line.
Laboratory,
FDA,
GxP,
Use,
Methodology,
Springer Nature,
Computation,
University,
Engineering,
Medicine,
Patient safety,
Device,
Computer simulation,
Partnership,
Medical device CM&S is also a very promising technology into the broader narrative of advancing regulatory science and healthcare innovation.
Key Points:
- CM&S is also a very promising technology into the broader narrative of advancing regulatory science and healthcare innovation.
- The book underscores the necessity for guidelines akin to the GxP standards, yet specifically tailored for in silico methodologies.
- It leverages the ASMEV&V40 – 2018 standard as a model, proposing a consensus-driven framework to support CM&S with good practices applicable across the spectrum of medical solutions.
- This partnership illustrates the proactive engagement between regulatory agencies and the scientific community to foster advancements in medical product development.
Laboratory,
FDA,
GxP,
Use,
Methodology,
Springer Nature,
Computation,
University,
Engineering,
Medicine,
Patient safety,
Device,
Computer simulation,
Partnership,
Medical device CM&S is also a very promising technology into the broader narrative of advancing regulatory science and healthcare innovation.
Key Points:
- CM&S is also a very promising technology into the broader narrative of advancing regulatory science and healthcare innovation.
- The book underscores the necessity for guidelines akin to the GxP standards, yet specifically tailored for in silico methodologies.
- It leverages the ASMEV&V40 – 2018 standard as a model, proposing a consensus-driven framework to support CM&S with good practices applicable across the spectrum of medical solutions.
- This partnership illustrates the proactive engagement between regulatory agencies and the scientific community to foster advancements in medical product development.
Retrieved on:
Monday, February 12, 2024
Pharmacology,
AstraZeneca,
Pharmacy,
Section,
Intelligence,
Research and development,
Drug development,
MIDD,
Master,
Doctor of Philosophy,
Lead,
Business,
Uppsala University,
Patient,
Infection,
University of Gothenburg,
Master of Science,
Medicine MILAN, Feb. 12, 2024 /PRNewswire/ -- InSilicoTrials is thrilled to announce the appointment of Dr. Daniel Röshammar as Vice President of Research & Development, marking a significant step forward in our mission to revolutionize healthcare through the power of in silico technology.
Key Points:
- MILAN, Feb. 12, 2024 /PRNewswire/ -- InSilicoTrials is thrilled to announce the appointment of Dr. Daniel Röshammar as Vice President of Research & Development, marking a significant step forward in our mission to revolutionize healthcare through the power of in silico technology.
- With an illustrious career spanning various therapeutic areas, including cardiovascular diseases, infectious diseases, reproductive health, and oncology, Dr. Röshammar's boasts significant expertise in clinical drug development, clinical pharmacology, and pharmacometrics.
- "Daniel's appointment is a testament to our commitment to leading the way in AI and simulation tools for drug development," said Luca Emili, CEO of InSilicoTrials.
- In his capacity as Vice President of Research & Development at InSilicoTrials, Dr. Daniel Röshammar will harness his profound knowledge in pharmacometrics and model-informed drug development to directly oversee and innovate our R&D projects.
Retrieved on:
Monday, February 12, 2024
Pharmacology,
AstraZeneca,
Pharmacy,
Section,
Intelligence,
Research and development,
Drug development,
MIDD,
Master,
Doctor of Philosophy,
Lead,
Business,
Uppsala University,
Patient,
Infection,
University of Gothenburg,
Master of Science,
Medicine MILAN, Feb. 12, 2024 /PRNewswire/ -- InSilicoTrials is thrilled to announce the appointment of Dr. Daniel Röshammar as Vice President of Research & Development, marking a significant step forward in our mission to revolutionize healthcare through the power of in silico technology.
Key Points:
- MILAN, Feb. 12, 2024 /PRNewswire/ -- InSilicoTrials is thrilled to announce the appointment of Dr. Daniel Röshammar as Vice President of Research & Development, marking a significant step forward in our mission to revolutionize healthcare through the power of in silico technology.
- With an illustrious career spanning various therapeutic areas, including cardiovascular diseases, infectious diseases, reproductive health, and oncology, Dr. Röshammar's boasts significant expertise in clinical drug development, clinical pharmacology, and pharmacometrics.
- "Daniel's appointment is a testament to our commitment to leading the way in AI and simulation tools for drug development," said Luca Emili, CEO of InSilicoTrials.
- In his capacity as Vice President of Research & Development at InSilicoTrials, Dr. Daniel Röshammar will harness his profound knowledge in pharmacometrics and model-informed drug development to directly oversee and innovate our R&D projects.
Research,
Food,
Deficit spending,
MIRA,
Disorder,
THC,
DSM-IV codes,
Learning,
FDA,
Artificial intelligence,
Cognition,
Machine learning,
Buspirone,
Neuropharmacology,
MD,
Drug discovery,
Medical cannabis,
Memory,
Anxiety disorder,
AI,
Drug development,
Pharmaceutical industry,
Medical device,
Appetite,
Anxiety BALTIMORE, Dec. 4, 2023 /PRNewswire/ -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "Company"), an innovative pre-clinical-stage pharmaceutical company focused on neurologic and neuropsychiatric disorders, has released new data from artificial intelligence (AI) simulations that show that, compared to plant-based medical marijuana, there may be significant potential advantages to the therapeutic potential of MIRA1a, such as its potential to offer a superior anti-anxiety treatment, increased cognition and without the increased appetite associated with THC.
Key Points:
- The simulations on MIRA1a were conducted in conjunction with the Company's strategic collaboration with InSilicoTrials , a company specializing in leveraging AI and simulations to enhance drug and medical device development.
- In silico analysis is a computational technique that uses AI to predict the interaction between drugs and their targets.
- The simulations suggest that MIRA1a's agonistic action on the 5-HT1a receptor aligns with established anxiolytic properties in medications like Buspirone and certain SSRIs.
- "In the groundbreaking field of neuropharmacology, artificial intelligence and machine learnings have ushered in a new era of drug discovery and analysis," said Adam Kaplin, MD, Ph.D., President and Chief Scientific Officer of MIRA Pharmaceuticals.
Retrieved on:
Thursday, November 16, 2023
Osteoporosis,
Organization,
Data science,
European Commission,
ALS,
IST,
Big data,
European Health Management Association,
COVID-19,
Civil service commission,
Patient,
Multimedia,
Health,
Breast,
Digital,
Pharmacy,
ESNA,
Multiple sclerosis,
Cancer,
Partnership,
AI,
Microsoft,
Quality of life,
Horizon,
Rahila Hadea Cudjoe,
Environment,
Tuberculosis,
Smart device,
Aneurysm,
Pharmaceutical industry,
Medical device MILAN, Nov. 16, 2023 /PRNewswire/ -- InSilicoTrials (IST), a pioneering innovator in the field of clinical trials and healthcare technology, has been awarded the prestigious 2023 Innovation Radar Prize in the AI and Smart Devices category.
Key Points:
- MILAN, Nov. 16, 2023 /PRNewswire/ -- InSilicoTrials (IST), a pioneering innovator in the field of clinical trials and healthcare technology, has been awarded the prestigious 2023 Innovation Radar Prize in the AI and Smart Devices category.
- This recognition comes as a testament to IST's commitment to revolutionize drug and medical device development by harnessing the power of in silico technology.
- The Innovation Radar Prize, initiated by the European Commission in 2015, celebrates innovators who have received EU funding and are working to transition their innovations from the laboratory to the market.
- InSilicoTrials is honored to accept the 2023 Innovation Radar Prize in the AI and Smart Devices category and extends our gratitude to the European Commission, HaDEA, and our partners for acknowledging the significance of our work in reshaping the landscape of medical research and patient care.
Retrieved on:
Thursday, November 16, 2023
Osteoporosis,
Organization,
Data science,
European Commission,
ALS,
IST,
Big data,
European Health Management Association,
COVID-19,
Civil service commission,
Patient,
Health,
Breast,
Digital,
Pharmacy,
ESNA,
Multiple sclerosis,
Cancer,
Partnership,
AI,
Microsoft,
Quality of life,
Horizon,
Rahila Hadea Cudjoe,
Environment,
Tuberculosis,
Smart device,
Aneurysm,
Pharmaceutical industry,
Medical device MILAN, Nov. 16, 2023 /PRNewswire/ -- InSilicoTrials (IST), a pioneering innovator in the field of clinical trials and healthcare technology, has been awarded the prestigious 2023 Innovation Radar Prize in the AI and Smart Devices category.
Key Points:
- MILAN, Nov. 16, 2023 /PRNewswire/ -- InSilicoTrials (IST), a pioneering innovator in the field of clinical trials and healthcare technology, has been awarded the prestigious 2023 Innovation Radar Prize in the AI and Smart Devices category.
- This recognition comes as a testament to IST's commitment to revolutionize drug and medical device development by harnessing the power of in silico technology.
- The Innovation Radar Prize, initiated by the European Commission in 2015, celebrates innovators who have received EU funding and are working to transition their innovations from the laboratory to the market.
- InSilicoTrials is honored to accept the 2023 Innovation Radar Prize in the AI and Smart Devices category and extends our gratitude to the European Commission, HaDEA, and our partners for acknowledging the significance of our work in reshaping the landscape of medical research and patient care.
